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Abstract
The polymeric immunoglobulin receptor (pIgR) ensures the transport of dimeric immunoglobulin A (dIgA) and pentameric
immunoglobulin M (pIgM) across epithelia to the mucosal layer of for example the intestines and the lungs via transcytosis.
Per day the human pIgR mediates the excretion of 2 to 5 grams of dIgA into the mucosa of luminal organs. This system
could prove useful for therapies aiming at excretion of compounds into the mucosa. Here we investigated the use of the
variable domain of camelid derived heavy chain only antibodies, also known as VHHs or NanobodiesH, targeting the human
pIgR, as a transport system across epithelial cells. We show that VHHs directed against the human pIgR are able to bind the
receptor with high affinity (,1 nM) and that they compete with the natural ligand, dIgA. In a transcytosis assay both native
and phage-bound VHH were only able to get across polarized MDCK cells that express the human pIgR gene in a basolateral
to apical fashion. Indicating that the VHHs are able to translocate across epithelia and to take along large particles of cargo.
Furthermore, by making multivalent VHHs we were able to enhance the transport of the compounds both in a MDCK-hpIgR
and Caco-2 cell system, probably by inducing receptor clustering. These results show that VHHs can be used as a carrier
system to exploit the human pIgR transcytotic system and that multivalent compounds are able to significantly enhance the
transport across epithelial monolayers.
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Introduction
All cavities of the human body are lined by epithelial tissue.
Epithelia are generally a single layer of cells which are connected
by junctions to form a barrier between the inside of the body and
lumina. Epithelial cells are polarized, in that they have a
segregated plasma membrane (apical and basolateral membrane)
and a partly segregated endosomal system (e.g. basolateral early
endosomes and apical recycling endosomes). Although epithelia
serve as a barrier, they do have the ability to specifically transport
molecules across via several means. One way is the transport
pathway called transcytosis, which is a receptor mediated vesicular
transport route that connects the apical and basolateral sides of the
cell, thereby giving the body a way to selectively take up and
secrete molecules [1]. Several receptors have been described to be
able to transport molecules across epithelia via the transcytotic
transport route. One of these receptors is the polymeric
immunoglobulin receptor, which is able to transport dimeric
immunoglobulin A (dIgA) and to a lesser extent pentameric
immunoglobulin M (pIgM) across epithelial cells [2]. After
synthesis, the pIgR is delivered to the basolateral membrane
[3,4], from where it internalizes either with or without bound
dIgA/pIgM and subsequently moves via several transport
itineraries to the apical membrane [5]. A covalent interaction
via disulfide bridges will form en route between the pIgR and
dIgA/pIgM in the case the receptor has bound a ligand [6]. At the
apical membrane a large part of the pIgR ectodomain is cleaved
off by (an) as of yet unknown protease(s), giving rise to the
compound known as the secretory component. The secretory
component is thereby secreted, either with or without the dIgA/
pIgM into the mucosa [7,8]. Due to the covalent interaction, the
secretory component will remain attached to the dIgA, a
compound referred to as ‘secretory IgA’ (sIgA). Through this
interaction it gives the immunoglobulin more stability in the
mucosa [9]. By transporting immunoglobulins across the epithelia
of the intestines and lungs, the pIgR transcytotic system ensures
humoral defense in the mucosa against incoming pathogens.
Although the fate of the pIgR in trafficking might seem
unidirectional, a small percentage of pIgR present on the apical
membrane remains uncleaved and this population of receptors has
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bound to the receptor, swift recycling will occur to the apical
membrane. However, in case no ligand is bound, the receptor has
the ability to transcytose back to the basolateral membrane. A
classic example here, is the observation made a few years ago that
Streptococcus pneumoniae is able to make use of this latter transport
pathway to gain entry into the body [12,13]. So, although the
main transport vector of the receptor is towards the apical
membrane, there is also a small vector in the opposite direction.
The ability to traffic in both the basolateral-to-apical and apical-
to-basolateral direction makes the pIgR an interesting therapeutic
target that could mediate secretion of unwanted compounds out of
the body or mediate uptake of orally administered therapeutic
compounds into the body. Several groups have already published
studies of proteins which are able to bind to and transcytose with
the pIgR (Fab-fragments [14] and 9 amino acid peptides [15]).
Here, we have used VHH technology as a therapeutic approach,
since this platform has several advantages over the aforementioned
compounds. VHHs, therapeutically known as NanobodiesH, are
the isolated variable domains of heavy chain-only antibodies
derived from camelids [16]. They are small (,15 kD) and have
been recognized in literature for their therapeutic potential
because of their high chemical and physical stability, relatively
low production costs, and cleft binding capabilities. In addition,
the simple gene make-up of VHHs lends them well for genetic
cross linking of several VHHs in order to make multidomain
compounds. This makes optimization of the molecule easy because
either the affinity for the target can be increased by linking two
VHHs which bind the same protein (multivalency) or multispecific
proteins can be created by linking two VHHs with different
effector functions [17].
In this study we have performed phage display selections on
VHH libraries constructed from Llama glama immunised with
hpIgR ectodomain to select for compounds which can mediate
epithelial transcytosis. We show that the selected VHHs have high
affinity for the receptor and are able to transcytose with the
receptor across a monolayer of MDCK cells transduced with the
hpIgR gene and Caco-2 cells which endogenously express the
hpIgR. Furthermore, by making multivalent constructs, we were
able to increase the initial rate of entry and also the transcytotic
rate of one such compound, probably by inducing receptor
clustering on the basolateral membrane. Our data show that the
selected and optimised VHHs against the ectodomain of hpIgR
are a promising tool for unidirectional transport of cargo across
epithelial monolayers.
Results
Selection and validation of hpIgR binding VHHs
In order to obtain a source of VHHs that are able to bind to the
human polymeric immunoglobulin receptor (hpIgR), two Llama
glama’s were immunized with the recombinant ectodomain of
hpIgR. After five boosts with similar amounts of antigen, a blood
sample was taken and analysed for immune reactivity on a pIgR
coated plate, which indicated pIgR reactive antibodies. Lympho-
cytes were subsequently extracted and a phage display library was
made. With these immune libraries two successive rounds of
selection were done on coated hpIgR ectodomain. Bound phages
were eluted using trypsin (total bound phages). The first round
yielded approximately 2610
7 total bound phages for both libraries
(fig. 1A), which was enriched in comparison with a non-coated
control (2610
4 phages). In order to select for VHHs binding to the
dIgA binding epitopes on pIgR, IgA was used to compete in the
re-binding of released phages, thereby specifically selecting those
VHHs that bind the pIgR on the IgA binding site. When phages
were eluted with IgA, 2610
6 phages were released from the coated
plate. The control, IgG eluted well, yielded similar amounts of
eluted phage as the wells eluted with IgA. The output of the IgA
eluted wells was used for another round of selection in a similar
manner as the first round to further enrich for pIgR binding
VHHs. Here, a total of 4610
8 bound phages were eluted with
trypsin for both libraries (with 2610
4 phages for the non-coated
control) and 4610
7 phages were eluted with IgA which in both
cases (trypsin and IgA) was higher than the first round whilst input
was roughly the same, indicating an enrichment of hpIgR binding
VHHs.
Monoclonal VHHs were picked out of a polyclonal output and
tested for their ability to bind coated hpIgR ectodomain. Of the
positive, sequentially unique, monoclonal VHHs, four clones were
selected on the basis of their promising binding characteristics.
These four VHHs were only able to pull down the hpIgR from a
hpIgR transduced MDCK cell lysate and not from a MDCK
control lysate (fig. 1B), whilst a negative control VHH directed
against the human transferrin receptor was not able to pull down
the hpIgR.
Specificity was furthermore tested by analysing competition of
the four VHHs with the IR800 labelled physiological ligand, dIgA
(fig. 1C). All four VHHs were able to compete to different extents
with dIgA for binding to coated hpIgR ectodomain. IC50 values of
the constructs ranged from ,1 nM (4b11) to ,70 nM (1e7). In
accordance with this latter feature, these four VHHs were able to
pull down secretory component (hSC) from the cultured medium
of polarized MDCK-hpIgR cells (fig. 1D), whilst purified secretory
IgA (sIgA) could not be precipitated by these VHHs (fig. 1E),
indicating that the covalent interaction between dIgA and hSC
blocks the binding site of the VHHs.
Finally, the affinity of the VHHs was determined by compound
titration on live cells. VHHs were titrated and allowed to bind
non-polarized MDCK-hpIgR cells at 4uC. Quantitation of the
bound VHHs yielded sigmoid curves typical for binding assays.
Bmax was roughly the same for all compounds, however there
were differences in the concentration at which half-maximal
binding was observed, which is a measure of affinity. Plotting
with a ‘one-site specific binding’ algorithm yielded KD values for
the four VHHs (fig. 1F). Of the selected VHHs, 4b11 appears to
bind strongest to the receptor, having a KD value of roughly
0.8 nM. The other VHHs seem to have affinities between 1 and
2 nM. Together these data indicate that these VHHs are all able
to bind specifically and with high affinity to the unoccupied
hpIgR.
Selected VHHs internalize into cells expressing hpIgR
To see whether these VHHs are able to internalize into
polarized MDCK cells in a hpIgR dependent fashion, MDCK
cells expressing hpIgR were grown on transwell inserts. Para-
cellular leakage was analysed using lucifer yellow and was found to
be negligible after 5 days of culturing. 1 mM of the four selected
VHHs was applied either 20 min basolaterally or 60 min apically
on the polarized MDCK cells at 37uC. Cells were subsequently
fixed and internalised VHH was immunostained with anti-myc tag
antibodies and analysed by confocal microscopy. All four anti-
hpIgR VHHs were able to internalize into polarized MDCK-
hpIgR cells from both the basolateral and, albeit more poorly,
apical side (fig. 2A; only VHH 4b7 is depicted, however staining
was similar for all VHHs). No internalization of the VHHs was
seen in control MDCK cells that do not harbour hpIgR (fig. 2A).
VHH staining in MDCK-hpIgR cells showed puncta which partly
colocalized with the early endosomal marker EEA1, affirming that
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internalization (fig. S1; again only 4b7 is shown).
Next, internalization rates of the four VHHs were determined.
VHHs were diluted to 1 mM and applied to non-polarized
MDCK-hpIgR cells for varying times at 37uC. Internalization
was stopped by putting the cells on ice. The VHHs still present on
the outside surface were removed by incubating the cells on ice
with 25 mg/ml trypsin for 45 min. This protocol was beforehand
shown to be sufficient to remove any surface bound VHH (data
not shown). Internalized VHH was subsequently immunolabelled
with an infrared dye (IR-800) and quantitated as described in the
experimental procedures. Data are presented as the intensity of
internalized VHH over the intensity of total cells present in the
wells as determined by a fluorescent nuclear dye (Ivhh/Icells). This
in order to correct for any variation in the number of cells used in
the experiments (fig. 2B). An irrelevant VHH which specifically
recognizes human transferrin receptor and therefore serves as an
indicator of fluid-phase uptake was used as a negative control. The
internalized amount of the irrelevant VHH was deducted from all
time points of the anti-hpIgR VHHs. Our data show that all
VHHs are actively taken up by these cells already at early time
points. The signal was seen to reach a plateau after ,8 min of
internalization time, possibly indicating that the receptor recycles
in non-polarized cells. The internalization rates of the four VHHs
are similar, probably reflecting constitutive internalization of the
receptor.
To test whether these VHHs have the potential to form a carrier
for therapeutic use, the constructs were assessed on their
transcytotic capacity. The VHHs were expressed on bacterio-
phages and used in transwell assays with polarized MDCK-hpIgR
cells. Phages were applied basolaterally and incubated for 5 hours
with the cells. The apical medium was subsequently harvested and
used to infect TG-1 bacteria to estimate the number of phages
transcytosed over 5 hours (fig. 2C). Phage input was chosen at that
concentration where the anti-hTfR VHH did not show any
transport across the polarized cells. At this concentration, specific
VHHs displayed different transcytotic capacities, 4b11 giving the
most transcytosed phages (mean=10.3206447) and 1e7 the least
(mean=937,66198) per hour. Apically added phages were not
able to significantly transcytose to the basolateral chamber (data
Figure 1. Selection and validation of VHHs against hpIgR. (A) Outputs of phage display selection on coated recombinant hpIgR ectodomain
with either trypsin or IgA elution for llama’s 97 and 98. (B) Pull down of VHHs with incubated cell lysate of MDCK control (right) or MDCK-hpIgR (left)
cells with the anti-his matrix Talon. Western blot with anti-hSC and anti-myc tag (VHH) (n=3). (C) A critical amount of IR800 labelled dIgA with
indicated amount of VHHs was incubated on MDCK-hpIgR cells at 4uC for 1.5 h. The normalized amount of IR800-dIgA is calculated and set out in the
graph against the VHH concentration (n=4) (s.e.m.’s are shown for all points). (D+E) Pull down of VHHs incubated in MDCK-hpIgR cultured medium
containing hSC (D) or with 4 mg/ml sIgA (E). Western blot with anti-hSC, anti-hIgA heavy chain and anti-myc (n=4). (F) VHHs were titrated and put on
cells for 1.5 h at 4uC. VHH presence was quantified by using anti-myc tag and D-a-M-IR800 antibodies. Quantification as described in experimental
procedures. KD determinations were done with a ‘one-site specific binding’ algorithm in Graphpad. (n=6).
doi:10.1371/journal.pone.0026299.g001
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VHHs are able to cross an epithelial monolayer from the
basolateral to the apical side to varying degrees and are able to
take along cargo (the virion) during this transport.
Optimization of transcytotic capacity
Recently it has been shown that the clustering of receptors
induces or augments their endocytosis, for example in the case of
the transferrin receptor [18] or the epidermal growth factor
receptor [19]. Specifically for the pIgR it has been suggested that
upon binding, dIgA induces pIgR dimerization and this feature
enhances pIgR endocytosis [20]. We hypothesized that a bivalent
construct, a construct with two identical heads genetically coupled
together, could induce dimerization of the pIgR and that a
biparatopic construct, a construct with two heads targeting two
different, non-overlapping, epitopes, could induce dimerization
and/or oligomerization of the receptor on the plasma membrane.
To test if the VHHs recognized different non-overlapping epitopes
on the hpIgR, epitope mapping of the selected VHHs was first
undertaken by means of competition assays. VHHs were produced
with either a myc- or flag-tag. Increasing concentrations of the
flag-tagged constructs were mixed with a critical amount of the
respective myc-tagged constructs and allowed to bind to a hpIgR
coated plate. After binding, myc-tag presence was quantified in the
wells. The flag version of each VHH was able to compete off the
corresponding myc version at increasing concentrations in all
cases, thereby validating the assay (fig. 3 and S2). Competition
could also be seen in the case of 1d2 and 4b11 at increasing
concentrations of the other compound, which indicates that they
bind to the same area on the receptor. The other two VHHs
appear to have unique binding sites as no other compound could
give competition except itself. So, within this set of selected VHHs
there appear to be three epitope groups despite the fact that all
VHHs compete with dIgA: the 1d2/4b11 epitope, the 4b7 epitope
and the 1e7 epitope.
Bivalent and biparatopic constructs were thus made using
different linker lengths (5, 15 and 25 gly4-ser1 repeats) to account
for possible preferred receptor orientations. An internalization
Figure 2. Selected VHHs internalize into and transcytose across polarized epithelial cells expressing hpIgR. (A) 1 mM of 4b7 VHH was
applied either basolaterally (for 20 min) or apically (for 60 min) on polarized MDCK-hpIgR cells and visualized after fixation with an anti-myc tag and
G-a-M-Alexa488 antibody and DAPI staining both in xy and xz plane (n=4). 1 mM of 4b7 VHH was applied to confluent MDCK control cells and
treated as above (n=4). (B) Internalization assay of selected VHHs. 1 mM VHH was incubated on cells at 37uC for 1, 3 or 7 min. Externally bound VHH
was removed with 25 mg/ml trypsin for 45 min on ice. Internalized VHH was immunolabelled with an anti-myc tag and D-a-M-IR800 antibodies.
Quantification of fluorescence is described in experimental procedures. Fluorescence intensities of the internalized amount is divided over the
amount of cells (To-pro3 nuclear stain) and plotted against time. The signal of the irrelevant anti-hTfR VHH was deducted from the specific VHH signal
and therefore represents the x-axis (n=12) (s.e.m.’s are shown for all points). (C) Transcytosis assay using VHH displaying phages. Phages were
applied basolaterally and incubated for 5 h. Amount of phages in apical medium is subsequently quantified as described in experimental procedures
and plotted per construct (n=4) (s.e.m.’s are shown for all points). Significance measurements were done by two-way ANOVA.
doi:10.1371/journal.pone.0026299.g002
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internalization efficiency. For all bivalent constructs a slight but
significant increase in internalization rate can be seen as compared
with the respective monovalent constructs (fig. 4A), suggesting that
the increase in endocytic rate is achieved via the dimerization of
the receptors. No significant differences were observed between
the different linker lengths. For the biparatopic constructs, a range
of different internalization rates can be seen (fig. 4B). The slowest
of which overlapped with the internalization speed of the bivalent
constructs (e.g. 1d2-15-4b7, fig. 4C), but the fastest rates outpaced
the bivalent constructs significantly (e.g. 4b11-5-1e7, fig. 4D). This
effect cannot be solely due to the affinity of the constructs, because
affinity determination on cells of several bivalent and biparatopic
constructs indicated that the affinity of the biparatopics, although
higher than monovalent constructs, did not exceed the affinity of
the bivalent VHHs (fig. 1F), which suggests that the effect of the
enhanced internalization rate is based on the endocytosis event.
Combined, we show that internalization rates can indeed be
improved by using bivalent and biparatopic constructs, possibly
through the clustering of the receptor.
To see whether an increased endocytic rate also correlated with
a higher transcytotic rate, 2 monovalent, 2 bivalent, 2 biparatopic
constructs and dIgA were compared for their transcytotic capacity
in a transwell assay. Constructs were radio-iodinated and probed
basolaterally in a 6 hour time course. The monovalent, bivalent
and one biparatopic construct all grouped together in a statistical
insignificantly differing group (fig. 5A). The physiological ligand,
dIgA, also had a similar transcytotic rate, which in literature has
been suggested to be a non-enhanced steady-state transcytosis
event in this model system [21]. However, one biparatopic
construct, 1d2-15-4b7, had an enhanced transcytotic capacity as
compared with all other constructs, transcytosing 5.66 more
efficiently than the best monovalent construct (4b11) and 406
better than the ligand, dIgA. This feature was also checked in a
Caco-2 cell system, which is a human intestinal cell line
harbouring endogenous expression of the pIgR. Expression levels
of hpIgR in Caco-2 are however a lot lower than in the transduced
MDCK system. Accordingly, transcytosed amounts are signifi-
cantly lower than the transcytotic capacities seen in the MDCK
cell system. In the Caco-2 cell system the physiological ligand did
show an enhanced transcytosis as compared with monovalent
VHH transcytosis (10 fold), which is not totally in correspondence
with what has been suggested in literature (compare [21] and
[22,23]). This transport was found to be partly dependent on
EGFR kinase activity as has been described [24] (fig. 5B). In the
Caco-2 system 1d2-15-4b7 also showed to be more effective in
transcytosing to the apical side as compared with monovalent
VHH (3.5 fold), however could not reach the same levels as the
physiological ligand. Both the monovalent and the biparatopic
transcytotic rates were hardly affected by addition of erlotinib (an
EGFR kinase inhibitor), suggesting that the pathways taken by
these VHHs reflect steady-state pIgR transcytosis and that the
increase in transcytotic rate of 1d2-15-4b7 is solely determined by
the increased endocytic rate seen in fig. 4C. These results show
that enhancement of endocytosis and transcytosis can be achieved
by using biparatopic VHH constructs.
Discussion
The aim of this study was to select single domain llama antibody
fragments that could exploit the pIgR transcytotic pathway.
Monovalent constructs were isolated from phage display libraries
and were found to transcytose across polarized epithelial
monolayers and to be able to take along large particles of cargo.
Biparatopic VHHs were constructed to optimize the transport and
were found to transcytose more efficiently over an epithelial cell
layer than the monovalent constructs. The ability of biparatopic
VHHs to use the hpIgR to excrete 3.5 times more efficiently than
the monovalent constructs makes them a very promising tool for
the removal of unwanted agents, like viruses, toxins and other
pathogens.
Previously, groups have shown that antibody fragments [23]
and small peptides [15] selected to bind to the pIgR are able to use
this receptor to enter cells and transcytose from the basolateral to
the apical side. Here, we show a similar mechanism but with a
different approach, namely with VHH technology. By making use
of the easy genetic manipulation of the VHH genes, we were able
to show that bivalent and biparatopic constructs were able to
enhance the endocytosis of the hpIgR significantly, suggesting that
these VHHs cluster the receptor and thereby speed up
internalization. However, only one VHH of a selected few showed
that increased endocytosis also correlated with a higher transcy-
totic capacity (1d2-15-4b7). This indicates that the system can be
delicate, as increased internalization not always leads to an
enhanced transcytotic capacity (e.g. 4b11-5-1e7). A possible
explanation could be that on the one hand clustering can result
in a heightened transcytosis rate but on the other hand can also
target the receptor towards another fate (e.g. degradation in the
lysosome or recycling back to the basolateral plasma membrane).
This probably depends on the way the receptors are clustered (i.e.
which epitope groups are linked). In this respect, the clustering
should not be restricted to the use of biparatopic constructs but
should also be possible with bivalent constructs. Screening of more
bivalent and biparatopic compounds might therefore yield other
VHHs that give similar results as 1d2-15-4b7.
The exact mechanism by which bivalent and biparatopic
constructs enhance the internalization rate is not clear. Although
rate enhancement through receptor clustering is a tempting
mechanism of action, other effects are not excluded by these
experiments. Cell binding of VHHs at a saturated (1 mM)
concentration in the internalization assays might lead to binding
of the biparatopic constructs to the cells with only one head. This
can theoretically mean that two constructs can bind the receptor at
the same time. Subsequent internalization would lead to two fold
more construct entering cells than the monovalent constructs per
Figure 3. Epitope mapping of VHHs. Myc-tagged VHHs were
incubated with increasing amounts of flag-tagged VHHs in an hpIgR
coated well for 2 h at room temperature. Myc tag presence was
subsequently quantified and competition therewith assessed. Compe-
tition is depicted in a chequer board diagram were black indicates
competing VHHs (n=2). See Figure S2 for raw data.
doi:10.1371/journal.pone.0026299.g003
Increased Constitutive Transcytosis of PIGR
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26299Figure 4. Bivalency enhances internalization. (A–D) Internalization assay of selected VHHs. 1 mM VHH was incubated on cells at 37uC for 1, 3 or
7 min. Externally bound VHH was removed with 25 mg/ml trypsin for 45 min on ice. Internalized VHH was immunolabelled with an anti-myc tag and
D-a-M-IR800 antibodies. Quantification of fluorescence is described in experimental procedures. Fluorescence intensities of the internalized amount
is divided over the amount of cells (To-pro3 nuclear stain) and plotted against time. The signal of the irrelevant anti-hTfR VHH was deducted from the
specific VHH signal and therefore represents the x-axis (n=12) (s.e.m.’s are shown for all points).
doi:10.1371/journal.pone.0026299.g004
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than monovalent constructs in the internalization assay. The
transcytosis assay, where a sub-saturated concentration was used
(1 nM), showed that the capacity of 1d2-15-4b7 to cross epithelial
monolayers is higher in both cell systems than the two fold increase
we would expect in this scenario, suggesting that another
mechanism must be at work. However, it is clear that more
experiments will need to be done to understand the exact mode of
action.
In literature it has been shown that human dIgA is not able to
enhance transcytosis via signal transduction when interacting with the
human pIgR in MDCK cells [21]. In this same paper, the authors
show that this also holds true for a human lung epithelial cell
carcinoma system having endogenous expression of the pIgR (Calu-3).
This in contrast to studies done in MDCK cells with rabbit pIgR
where they find that application of the human ligand to cells
expressing rpIgR indeed elicits a signal transduction cascade which
culminates in the enhancement of the transcytotic pathway [22]; an
effect which was not seen when Fabs targeting the receptor were
applied basolaterally [23]. Here, we find that human dIgA is indeed
not able to transcytose faster than monovalent antibody fragments in
the MDCK-hpIgR cell system. However, when applied to our human
intestinal cell system harbouring endogenous expression of the hpIgR,
we do see an enhancement of transcytosis when the ligand is applied
basolaterally; an effect which is EGFR kinase activity dependent as is
described for the MDCK-rpIgR cell system [24]. There are two
possible explanations for these discrepancies. Either 1) the pIgR
transcytotic system is differentially regulated in the human body
depending on the epithelial tissue (enhancement in the intestines, but
not the lungs) or 2) the genotype of either the Calu-3 or Caco-2
carcinoma cell line is altered as compared with the physiological
situation in such a fashion that the cells have a lack or gain of
expression of (a) certain gene(s) necessary to perform the transcytotic
enhancement. In vivo or primary cell based experiments will need to be
done to confirm this effect, however going by the MDCK-rpIgR and
Caco-2 studies and the observation that early signal transduction
mediators are activated in Calu-3 cells after pIgA stimulation, it seems
safe to assume that the transcytoticenhancement effect based on signal
transduction does occur in normal physiology.
The .10 fold higher affinity of the VHHs as compared to the
physiological ligand [25] and the enhanced internalization of the
bivalent constructs by receptor clustering make our VHH
constructs attractive targeting modules for the export of unwanted
molecules from the body. Currently, we are setting up in vivo
experiments to confirm the ability of these constructs to serve as a
carrier for removal of viruses by using multi-specific VHHs
harbouring anti-hpIgR and anti-virus targeting heads. However,
these first in vitro results are promising. They indicate that the
selected constructs are able to transport large particles of cargo
across artificial epithelial layers and that this transport can be
enhanced 3–4 fold when using biparatopic constructs.
Materials and Methods
Immunization, selection and VHH production
Two Llama glama’s were immunized with recombinant human
pIgR ectodomain (R&D systems, Abingdon, UK) and subsequent-
ly boosted five times (protocol as described in [26]). The immune
response of the animals was monitored by titration of blood
samples on coated hpIgR wells. Four days after the last boost,
lymphocytes were purified from a 200 ml blood sample by
centrifugation on a Ficoll discontinuous gradient (Pharmacia,
Uppsala, Sweden). RNA was subsequently extracted from these
cells using guanidium thiocyanate [27] and a phage display library
was prepared as has been described [28].
Phages displaying VHHs were produced by infecting phagemid
transformed TG-1 bacteria with helper-phage VCS-M13 (Phar-
macia, Uppsala, Sweden). The polyclonal phage pool was used for
selections on coated plates. Phages were put on hpIgR coated
plates (5, 0.5, 0 ug/ml) for 1 h shaking at room temperature.
Plates were subsequently washed 20 times with PBS 0.05% tween
and incubated with either 1 mg/ml trypsin for 20 min at room
temperature or 500 mg/ml IgA (Sigma-Aldrich, Zwijndrecht, The
Netherlands) for 4 h at room temperature. Trypsin activity was
stopped after the incubation period with 200 mM ABSF. The
solution now present in the wells was used to infect TG-1 bacteria
for rescue.
Bivalent and biparatopic constructs were made using 5, 15 or 25
glycine serine linkers between both heads. Constructs were
transformed in TG-1 bacteria and their production was induced
with 0.1 mM IPTG when bacteria reached log-phase. After
production, bacteria were frozen to release the periplasmic
fraction. Purification of the periplasmic VHHs was done with
the his-tag affinity matrix Talon (Clontech, St. Germain-en-Laye,
France) and eluted with 150 mM Imidazol.
Cell culture
MDCK type II (a kind gift of Dr. E. Regan-Klapisz, Utrecht
University) were transduced with MLV harbouring a retroviral
Figure 5. Transcytotic capacity of optimized constructs. (A+B)
1n M
125I radio-labelled VHH or dIgA was applied in the basolateral
chamber of polarized MDCK-hpIgR cells (A) or Caco-2 cells (B) grown on
transwell inserts. Apical medium was resorbed after each 2 h interval to
a maximum of 6 h and quantified separately. Amount of pmol that is
transcytosed is plotted against time. Leakage of a non-specific VHH
control was deducted from the specific signal (n=4) (s.e.m.’s are shown
for all points). Significance measurements were done by two-way
ANOVA.
doi:10.1371/journal.pone.0026299.g005
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control’) or the human pIgR cDNA (‘MDCK-hpIgR’) (the cDNA
was a kind gift of Prof. Dr. C.S. Kaetzel, University of Kentucky).
Virus was produced by transfecting the retroviral vector in HEK-
Qnx-cells with calcium-phosphate. These cells are themselves
stably transfected with genes necessary for virus production. Virus
was subsequently harvested the following days and put on MDCK
cells which were transiently transfected with the murine ecotrophic
receptor (which is necessary for virus infection). Cells were put on
250 mg/ml zeocin to select for transfected cells and subsequently
FACS sorted to give a cell population with homogenous expression
of hpIgR. Caco-2 cells were obtained from ATCC (ATCC
number=HTB-37; Wesel, Germany).
Cells were cultured in DMEM supplemented with 8.2% FCS,
16 penicillin/streptomycin (P/S) and 16 L-glutamine
(DMEM
+++; Invitrogen, Breda, The Netherlands) and kept in a
humidified, 5% CO2 stove at 37uC. Cells were passed on average
three times/week with trypsin (PAA, Co ¨lbe, Germany).
For polarized epithelial monolayers, 3610
5 cells were seeded per
transwell filter (Corning, prod. nu: 3493, Amsterdam, The Nether-
lands) and cultured in DMEM-8.2% FCS-16 L-glut for 5 days
(MDCK) or 21 days (Caco-2). Medium was refreshed every other
day. The day before the experiment, monolayer integrity was
checked with lucifer yellow (LY, Invitrogen, Breda, The Nether-
lands). Briefly, 25 mg/ml LY in DMEM-8.2% FCS-16L-glut was
added apically. A sample of the basolateral medium was taken at
t=0 and t=1 h and quantitated with a FLUOstar system (BMG
labtech, Isogen Lifescience, De Meern, The Netherlands). Papp was
subsequently calculated using the formula described here [29].
When Papp,1610
26 (MDCK) or Papp,5610
27 (Caco-2), cells
were assumed to have formed a tight, differentiated monolayer.
Cells were put on CO2 independent medium (+8.2% FCS,
penicillin/streptomycin and L-glut; Invitrogen, Breda, The Nether-
lands) after the measurement and put back into the stove overnight.
P/S was added for the radio-active transcytosis and immuno-
fluoresence assays, however was omitted for the phage-based assays.
Pull down
1.8610
6 MDCK-hpIgR or MDCK-control cells were seeded the
day before the experiment in a 6 wells plate. On the day of the
experiment cells were put on ice, washed once with PBS and
subsequently scraped with 40 ml/well RIPA buffer (20 mM Tris/HCl
pH 7.5; 150 mM NaCl; 1 mM EDTA; 0.1% SDS; 0.5% Triton X-
100). The buffer was resorbed from the wells plate, put in a reaction
tube along with an extra 160 ml/well RIPA buffer and incubated for
5 min on ice. The lysate was centrifugated for 5 min at 14.000 rpm to
remove cell debris. The supernatant was used as a source of cell-
derived hpIgR. Medium that was cultured for three days on polarized
MDCK-hpIgR cells was used as a source of hSC. The medium was
resorbed and dialysed against PBS with a 6–8 kD MWCO membrane
(Interchim, Montluc ¸on, France) overnight at 4uC.
100 ml of the MDCK-hpIgR lysate or 4 mg sIgA (Sigma-Aldrich,
Zwijndrecht, The Netherlands) was incubated with 10 mgV H H ,
20 ml 1:1 talon (Clontech, St. Germain-en-Laye, France) and 4 ml
PBS for 1.5 h at 4uC head-over-head. The same amount of VHH and
Talon was added to the hSC containing solution described above for
secretory component precipitation. Beads were precipitated by
centrifugation and washed once with 5 ml PBS and once with 1 ml
PBS. 30 ml sample buffer was added, boiled at 100uCa n ds e p a r a t e d
with SDS-PAGE. The gel was blotted and the membrane was
immunolabeled with M-a-Myc (9e10, courtesy of Dr. R.C. Roovers,
Utrecht University), G-a-Secretory Component & G-a-IgA heavy
chain (Sigma-Aldrich, Zwijndrecht, The Netherlands), R-a-MPO &
D-a-GPO (Invitrogen, Breda, The Netherlands).
Immunofluorescence
Cells were grown in transwell filters as described in the ‘Cell
Culture’ section. Cells were blocked with 1% Marvel DMEM
+++ for
15 min. VHHs werediluted to 1 mM in1% Marvel-DMEM
+++and
put on the cells for either 20 min (basolateral entry) or 1 h (apical
entry) at 37uC. Cells were put on ice, washed twice with cold PBS
and either directly fixed in 4% PFA for 15 min (basolateral entry) or
first stripped with 25 mg/ml trypsin in DMEM for 45 min on ice
and then fixed (apical entry). After fixation, cells were quenched at
room temperature with 50 mM NH4Cl-PBS for 10 min and
subsequently stained with M-a-Myc (4A6, Millipore, Amsterdam
ZO, The Netherlands), R-a-VHH (in-house made), M-a-EEA1
(BD Biosciences, Breda, The Netherlands), G-a-R-A555, G-a-M-
A488 (Invitrogen, Breda, The Netherlands) and DAPI (Roche,
Almere, The Netherlands) in PBS-0.1% BSA-0.25% saponin.
Filters are finally cut out, mounted with Slowfade (Invitrogen,
Breda,TheNetherlands)and imagedwith a ZeissLSM510confocal
laser scanning microscope.
dIgA purification and labelling
dIgA was obtained by purifying IgA from human plasma (a kind
gift of Dr. J.C. Stam, Utrecht University) using a CaptureSelect
IgA column (BAC, Leiden, The Netherlands) according to the
manufacturers protocol. The resulting IgA pool (both monomer as
dimer) was labelled with NHS-IR800CW (Li-Cor, Westburg,
Leusden, The Netherlands) in a protein:dye molar ratio of 1:4.1
and subsequently dialysed against PBS using 20 ml spin-columns
(MWCO=50.000 kD; Corning, Amsterdam, The Netherlands) to
get rid of unlabelled dye and used for competition assays. The
labelled protein pool was able to bind MDCK-hpIgR cells but not
MDCK control cells, indicating that only the labelled dIgA was
able to bind cells and not mIgA.
For radioactive transcytosis assays, the pool was further purified
using a Superdex 200 gel permeation column (GE Healthcare,
Hoevelaken, The Netherlands) thereby getting rid of more
monomeric IgA. This to ensure that iodine labelling was done
primarily on dIgA and that the bulk of protein loaded into the
basolateral chamber was hpIgR reactive.
Binding and competition assays
1.5610
6 cells were seeded the day before experimentation in a
96 wells plate. Cells were blocked with 1% Marvel-DMEM
+++ for
15 min at 37uC and subsequently cooled to 4uC for 15 min.
VHHs (either alone, with dIgA-IR800 or together) were diluted in
DMEM-1% Marvel and cooled at 4uC for 15 min. VHHs were
incubated for 1.5 h at 4uC, washed twice with ice-cold PBS, fixed
for 15 min with 4% PFA on ice and quenched with 50 mM
NH4Cl-PBS at room temperature for 10 min. VHHs were
immunolabelled with M-a-Myc (4A6, Millipore, Amsterdam
ZO, The Netherlands) and D-a-M-IR800 (Li-Cor, Westburg,
Leusden, The Netherlands) in PBS-0.1% BSA and quantitated
with an Odyssey imaging system (Li-Cor, Westburg, Leusden, The
Netherlands). No further labelling was done after fixation in the
competition assays using dIgA-IR800. Plotting was done with the




6 cells were seeded the day before experimentation in a
96 wells plate. Cells were blocked with 1% Marvel-DMEM
+++ for
15 min at 37uC. VHHs were diluted to 1 mM in DMEM-1%
Marvel and pre-heated to 37uC for 15 min. VHHs were incubated
for indicated time points on the cells at 37uC. Cells were
Increased Constitutive Transcytosis of PIGR
PLoS ONE | www.plosone.org 8 October 2011 | Volume 6 | Issue 10 | e26299subsequently put on ice, washed twice with ice-cold PBS, stripped
with 25 mg/ml trypsin in DMEM for 45 min on ice, washed once
with PBS, fixed for 15 min with 4% PFA on ice and quenched for
10 min with 50 mM NH4Cl-PBS at room temperature. VHHs
were subsequently immunolabelled with M-a-Myc (4A6, Milli-
pore, Amsterdam ZO, The Netherlands), D-a-M-IR800 (Li-Cor,
Westburg, Leusden, The Netherlands) and To-Pro-3 (Invitrogen,
Breda, The Netherlands) in PBS-0.1% BSA-0.25% saponin and
quantitated with an Odyssey imaging system (Li-Cor, Westburg,
Leusden, The Netherlands).
Radio-iodination
50 mg VHH or 20 mg dIgA was incubated with 0.2 mCi Na
125I
dissolved in a 0.5 M KPO4 buffer pH 7.5 in a tube which was
coated with 0.1 mg Iodo-gen (Sigma-Aldrich, Zwijndrecht, The
Netherlands) for approximately 10 min. The reaction was stopped
by addition of an excess 0.25 M KPO4 pH 7.5-1% BSA and the
mixture was subsequently put on an Ag-1-86resin column (Bio-
Rad, Veenendaal, The Netherlands) to separate free from labelled
radio-active dye. The percentage free dye was subsequently
determined by TCA precipitation and did not exceed 8% of total
amount of counts. A binding assay showed that most VHHs are
unaffected by the labelling. However, bivalent constructs har-
bouring VHH 1e7 did show some lack of binding.
Transcytosis assay
On the day of the experiment, cells were blocked in 1% casein
in CO2 independent medium (+8.2% FCS, L-glut and either with
or without P/S depending on whether phages were used in the
assay) for 15 min at 37uC. Phages were diluted in the same
blocking buffer so that there were 1.67610
9 phages in 500 ml. This
mixture was incubated for 5 h. Medium of the opposing chamber
was resorbed and 100 ml (1/3 of total volume) of this output was
mixed with log-phase TG-1 for 45 min at 37uC for infection.
Bacteria were subsequently put on ampicillin containing agar-
plates and grown overnight.
For iodinated transcytosis assays, cells were blocked in the same
fashion as above and 1 nM of radio-iodinated VHH/dIgA was
added to the basolateral chamber. 10 mM erlotinib or 0.1%
DMSO (Sigma-Aldrich, Zwijndrecht, The Netherlands) was
added 30 min before the start of the experiment and was present
during the whole time course. The apical medium was resorbed
after each two hour period up till a maximum duration of 6 h for
the experiment. Apical media were quantitated with a Perkin
Elmer Wizard counter (Groningen, The Netherlands).
Supporting Information
Figure S1 Colocalization study of internalized VHH 4b7
with endosomal marker EEA1. 1 mM VHH was applied
either apically for 1 h or basolaterally for 20 min. Cells were fixed
and immunolabelled with R-a-VHH (Alexa-555) and M-a-EEA1
(Alexa-488) and stained with DAPI.
(EPS)
Figure S2 Epitope mapping of VHHs. 30 nM of myc-VHH
is incubated with indicated amounts of flag-VHH in an hpIgR
coated well for 2 h at room temperature. Myc tag presence is
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